Following on Bristol Myers Squibb Company’s US Food and Drug Administration approval of the first-in-class TYK2 inhibitor Sotyktu (deucravacitinib) for moderate-to-severe plaque psoriasis in late 2022, numerous other firms are lining up to develop the next TYK2-targeting agent for autoimmune diseases. Alumis, Inc., with positive Phase II data, thinks it might have a best-in-class molecule in ESK-001.
Alumis Looks To Stand Out From The TYK2 Crowd With Psoriasis Data
Company Announces Series C Raise
The privately held company announced data at AAD showing high PASI 75 rates in both a randomized Phase II trial and an open-label extension study.
